Table 4.

Correlations between the number of in vivo nicotinic binding sites and the inhibition of CSF AChE-S and AChE-R variants after 12 months.

		AChE-R variant (%Inhibition)		AChE-S variant (%Inhibition)		Total AChE (%Inhibition)
The nicotinic binding sites in brain region (1-k2*)		r (n = 8)	p < 0.05	r (n = 8)	p < 0.05	r (n = 8)	p < 0.05
Cortical regions	L	−0.70	0.052	−0.67	0.059	−0.73	0.037
	R	−0.75	0.028	−0.70	0.050	−0.77	0.022
Overall brain regions	L	−0.76	0.027	−0.72	0.043	−0.78	0.019
	R	−0.79	0.018	−0.70	0.054	−0.79	0.016
Average cortical regions		−0.74	0.034	−0.71	0.049	−0.76	0.025
Average overall brain regions		−0.78	0.019	−0.72	0.044	−0.80	0.015
Whole brain		−0.79	0.017	−0.75	0.029	−0.82	0.011

All r-values are correlation coefficient. Some of the correlations are graphically illustrated in Figure 5. k₂* = the binding constant for the PET tracer. The k₂* values for ¹¹C-nicotine binding are exemplified in Figure 3 and Figure 5C. PET, Positron emission tomography; CSF, Cerebrospinal fluid; AChE-S, Synaptic acetylcholinesterase splice variant protein; AChE-R, Read-through acetylcholinesterase splice variant. The percentages are calculated relative to the patients’ baseline value.